Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469846 | 1.00 | LDHA (0.62) | LDHACYP1A2CA2CA1CA9 | |
| SCHEMBL13223071 | 0.88 | CDK2 (0.62) | LDHACYP1A2CA2CA1CA9 | |
| SCHEMBL15461564 | 0.81 | CYP1A2 (0.56) | LDHACYP1A2GLO1CYP2A6ALDH1A1 | |
| SCHEMBL640546 | 0.79 | CYP1A2 (0.54) | LDHACYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL18889781 | 0.79 | LDHA (0.62) | LDHACA2CA1CA9CDK2 | |
| SCHEMBL11684694 | 0.79 | CYP1A2 (0.54) | LDHACYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL2662857 | 0.79 | CYP1A2 (0.54) | LDHACYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL11192937 | 0.78 | CYP1A2 (0.52) | LDHACYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL30274447 | 0.78 | CYP1A2 (0.52) | LDHACYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL9138970 | 0.77 | CDK2 (0.78) | LDHACA2CA1CA9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-1104424-A4 | PROCESS FOR THE SYNTHESIS OF CARBAPENEM INTERMEDIATES, AND COMPOUNDS PRODUCED | MERCK & CO INC (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1140823-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| EP-1104424-A1 | PROCESS FOR THE SYNTHESIS OF CARBAPENEM INTERMEDIATES, AND COMPOUNDS PRODUCED | Merck & Co., Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000039088-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-06 | — | — | WO | disclosed |
| EP-0981522-A1 | PROCESS FOR SYNTHESIZING CARBAPENEM INTERMEDIATES | Merck & Co., Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1999065921-A1 | PROCESS FOR THE SYNTHESIS OF CARBAPENEM INTERMEDIATES, AND COMPOUNDS PRODUCED | MERCK & CO., INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1998051677-A1 | PROCESS FOR SYNTHESIZING CARBAPENEM INTERMEDIATES | MERCK & CO., INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | AARS1, GARS1, ASNS | LDHA 1661/4885CYP1A2 3507/4885CA2 4520/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | LDHA 3237/4885CYP1A2 2010/4885CA2 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.